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Abstract
Background: Several studies have demonstrated that array comparative genomic hybridisation (CGH) for genome-
wide imbalance provides a substantial increase in diagnostic yield for patients traditionally referred for karyotyping
by G-banded chromosome analysis. The purpose of this study was to demonstrate the feasibility of and strategies
for, the use of array CGH in place of karyotyping for genome imbalance, and to report on the results of the
implementation of this approach.
Results: Following a validation period, an oligoarray platform was chosen. In order to minimise costs and increase
efficiency, a patient/patient hybridisation strategy was used, and analysis criteria were set to optimise detection of
pathogenic imbalance. A customised database application with direct links to a number of online resources was
developed to allow efficient management and tracking of patient samples and facilitate interpretation of results.
Following introduction into our routine diagnostic service for patients with suspected genome imbalance, array
CGH as a follow-on test for patients with normal karyotypes (n = 1245) and as a first-line test (n = 1169) gave
imbalance detection rates of 26% and 22% respectively (excluding common, benign variants). At least 89% of the
abnormalities detected by first line testing would not have been detected by standard karyotype analysis. The
average reporting time for first-line tests was 25 days from receipt of sample.
Conclusions: Array CGH can be used in a diagnostic service setting in place of G-banded chromosome analysis,
providing a more comprehensive and objective test for patients with suspected genome imbalance. The increase
in consumable costs can be minimised by employing appropriate hybridisation strategies; the use of robotics and
a customised database application to process multiple samples reduces staffing costs and streamlines analysis,
interpretation and reporting of results. Array CGH provides a substantially higher diagnostic yield than G-banded
chromosome analysis, thereby alleviating the burden of further clinical investigations.
Background
Karyotype analysis of G-banded chromosomes is the
cytogenetic standard for the detection of copy number
imbalance across the genome, or balanced chromosome
rearrangements, in children with such features as idio-
pathic developmental delay, learning difficulties, conge-
nital abnormalities or autism. However, this technique
has a resolution of only 3-5 Mb, and interpretation is
operator-dependent, requiring highly trained and specia-
lised staff to carry out the analysis. Higher resolution
targeted tests such as fluorescence in situ hybridisation
(FISH) [1] and multiplex ligation-dependent probe
amplification (MLPA) [2,3] have, over the years, been
added to the cytogenetic repertoire in order to increase
the diagnostic yield in this group of patients.
Comparative Genomic Hybridisation (CGH) was first
introduced in the early 1990s for the detection of DNA
amplification in tumours [4], and used metaphase
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array CGH, where short stretches of DNA on glass
slides are used as targets instead of metaphase spreads,
increased the resolution of the CGH approach and
allowed the implementation of this test for more wide-
spread use, particularly in tumour cytogenetics [5,6].
Array CGH has the potential to deliver a higher resol-
ution test compared with the 3-5 Mb limit of G-banded
chromosome analysis, and has added advantages of
objectivity and high throughput. However, the introduc-
tion of this test into constitutional diagnostic cyto-
genetic services has been slow, mainly due to the
expense of the consumables and to the wide-spread and
established acceptance of karyotype analysis as the first-
line test for genome-wide copy-number imbalance.
We have validated array CGH by testing and compari-
son of different platforms and hybridisation and analysis
strategies, and introduced the validated protocol as a
first-line test for patients with suspected copy number
imbalance. Here we describe our validation studies,
and the results of our diagnostic service testing from
04/2008 to 12/2009.
Methods
Patients
In the initial, validation, phase of this study (06/2006 to
03/2008), DNA from patients with known abnormalities,
detected by G-banded chromosome analysis, was tested
to confirm and validate the array procedure. In addition,
patients considered likely to have submicroscopic chro-
mosome imbalance, but with normal karyotypes, were
selected and referred by our Clinical Genetics team.
Results were reported as research findings only. When
array CGH was introduced as a validated procedure (04/
2008), testing was still restricted to those referred
through our clinic following a stringent gate keeping of
any requests. For these patients, formal diagnostic reports
were issued. Genetic testing in the UK is funded by the
National Health Service (NHS), with testing approved
and commissioned by local NHS genetics commissioning
bodies, based on evidence of test cost-effectiveness; fol-
lowing costings approval by our NHS genetics Commis-
sioners, array CGH was introduced as a first line test in
place of karyotype analysis on 05/2009, and was then
applied to all samples from our region with referral indi-
cations suggesting copy number imbalance.
Array platforms
BAC arrays
VIB 1 Mb (MicroArray Facility, VIB, Belgium) and
Cytochip (BlueGnome, UK).
Oligonucleotide arrays
Agilent (USA) 4 × 44 K platform with catalogue design
014950 and Wessex NGRL design 017457 (a modified
catalogue design shifting probe coverage away from can-
cer-related regions and towards constitutional syn-
dromes http://www.ngrl.org.uk/wessex/arraycgh.htm.
DNA extraction and QC
DNA was extracted from blood samples in EDTA using
the Chemagic Automated DNA Separation System
(Chemagen, Germany) following the manufacturer’s
instructions. All DNA was quantified by spectrophoto-
metry (Nanodrop, USA) and checked for degradation
on an agarose gel. Degraded DNA was not used; new
samples were requested for these cases.
Labelling DNA for array CGH
DNA (1 μg) was labelled using CGH Labelling Kit for
BAC Arrays (Enzo Life Sciences, USA) or CGH Label-
ling Kit for Oligo Arrays (Enzo Life Sciences, USA) as
appropriate, following the manufacturer’s instructions.
Purification and QC of labelled DNA
Labelled DNA was purified post- labelling using QIA-
quick PCR Purification Kit (Qiagen, USA) following the
manufacturer’s instructions. Labelling efficiency and
yield was assessed by spectrophotometry (Nanodrop,
USA).
Processing arrays
Hybridisation, washing and scanning of arrays was per-
formed following the manufacturers’ protocols.
Hybridisation strategies
Three different strategies were considered:
i) “dye swap” - hybridisation of patient DNA against
control DNA, with a repeat assay but with labelling
in opposite colours. Two arrays were required for
each patient sample, and this strategy gave confi-
d e n c et h a tt h ea r r a yf i n d i n g sw e r en o ta r t e f a c t u a l ,
and controlled for bias in cyanine (Cy) dye labelling
reaction efficiencies.
ii) “loop” [7]- three patient samples labelled in each
of two colours, then each sample hybridised against
the other two patient samples. Only one array was
required for each patient sample, and if the two
labelling runs were carried out on separately-
accessed DNA aliquots, then no confirmation of
sample identity was required. This strategy also gave
confidence that the array findings were not artefac-
tual, and controlled for bias in Cy dye labelling reac-
tion efficiencies.
iii) “patient/patient” - differentially-labelled patients
hybridised against each other. Patients were pheno-
type mismatched as any shared imbalance would not
be detected. Cy dye ratios informed “ownership” of
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indicate deletion and duplication respectively), which
was confirmed by a second array or by MLPA for
any syndromic imbalance covered by MLPA kits
P064 and P245 (~6% of cases; MRC-Holland, Neth-
erlands). This second test also confirmed sample
identity. Therefore the first round of array testing
required half an array; for each detected imbalance
(in approximately 25% of patients), a further half
array is required. This therefore resulted in an over-
all expenditure of 5/8 of an array per patient, provi-
ding substantial cost savings over other approaches.
Array data analysis
All arrays were scanned at 5 μm resolution (Agilent,
USA).
BAC arrays
Image quantification, array quality control and aberra-
tion detection were performed using BlueFuse software
(BlueGnome, UK). 95% of array data was required to
pass QC. Samples failing this QC were repeated. A nor-
mal range for log2 fluorescence ratios was set to 0 +/- 4
SD.
Oligo arrays
Image quantification, array quality control and aberra-
tion detection were performed using Feature Extraction
and DNA Analytics software packages (Agilent, USA)
for oligo arrays. Manufacturer’s recommendations were
followed. 95% of array data was required to pass QC.
Samples failing this QC were repeated. Two rounds of
aberration calling were employed, ADM-2 algorithm at
threshold 6 (with a 3 probe sliding window providing a
mean detection interval of 200 kb) for detection of copy
number imbalance, and ADM-1 algorithm at threshold
6 for detection of low-level mosaicism. Each called aber-
ration was assessed by an analyst to provide a further
measure of quality, to examine the genomic context of
the aberration and to identify any specific genes/regions
where further investigations might be required.
Fluorescence in situ hybridisation
BAC array findings were confirmed by fluorescence in
situ hybridisation (FISH) using the same clones (Blue-
gnome, UK and BACPAC, Sanger Institute, UK) as on
the array [8].
Multiplex ligation-dependent probe amplification
MLPA was used to confirm imbalance of syndromic
regions represented in MLPA kits P064 and P245
(MRC-Holland, Netherlands). Furthermore, inheritance
studies were performed by incorporating custom-
designed MLPA probes, specific for loci within the
region of imbalance, into MLPA kit P200 (MRC-
Holland, Netherlands). Custom MLPA probes were
designed using the H-MAPD tool [9]. All MLPA reac-
tions were performed following the manufacturer’s
instructions.
QF-PCR
Quantitative Fluorescence PCR was carried out as pre-
viously described [10]
Reporting
Imbalances of regions represented in the Database of
Genomic Variants (DGV) [11] as being present in the nor-
mal population (in at least three non-BAC based studies)
were recorded but not reported. All other imbalances out-
side areas of known syndromic imbalance were reported
as preliminary findings, with a request for parental blood
samples to establish inheritance. Inherited imbalances
were reported as probably benign, although “unusual fea-
tures shared by the proband and carrier parent may be
associated with the imbalance”. Genes in regions of
de novo imbalance were described if considered relevant
to the referral indication. The average reporting time for
first-line tests was 25 days from receipt of sample.
Final diagnostic service protocol
Patient samples were processed as detailed above, on the
Agilent 44 K platform (Wessex NGRL design 017457). A
patient/patient hybridisation strategy provided substan-
tial consumable and labour savings while maintaining
diagnostic yield. Figure 1 shows an example workflow
for two patients, one of whom carries an imbalance,
that are hybridised against each other. For findings not
present in DGV, Cy3/Cy5 signal ratios were used to
determine which hyb partner carried the imbalance. A
second follow-up array was used to confirm imbalance
in this patient, before reporting both hyb partners. Once
parental samples were received, custom MLPA or array
testing were used as appropriate for inheritance studies.
Results
Karyotype audit
Array CGH testing does not detect balanced rearrange-
ments; we therefore audited a 10-year period of karyo-
type results from our laboratory, which showed that of a
total of 36,663 postnatal blood samples received, 4
(0.0001%) were found to have de novo reciprocal
translocations.
Array validation
Both BAC array and oligoarray validation included “self-
self” hybridisations and DNA from cases of known
imbalance including trisomies for chromosomes 13 and
18, and deletions and duplications ranging from 0.5-7.1
Mb. Both array platforms gave the expected results from
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abnormalities, a number of patients with normal karyo-
types but considered likely to carry imbalance were also
tested. Where imbalance was detected by BAC array,
FISH with the abnormal clones was carried out where
possible. For 3/16 (18%) single clone results, the FISH
result was not concordant with the BAC array findings.
This was considered to be due to the differing sensitiv-
ities of the techniques. All larger imbalances detected by
BAC arrays were confirmed by FISH. Abnormalities
detected on oligoarrays were followed up by a variety of
techniques (MLPA, QF-PCR, retrospective G-banded
chromosome analysis) in 68 cases; no discrepancies
were found.
42 patients (with normal karyotypes) were tested on
both BAC and oligo array platforms. 30 of these gave
normal results on both platforms while 6 gave abnormal
results on both platforms. In these concordant cases
(Table 1), the resolution of the breakpoints given by the
oligo arrays was higher than that by the BAC arrays,
due to higher probe density across the genome and the
smaller size of the oligo probes. The remaining 6 discor-
dant results (Table 2) all demonstrate imbalances that
were not detected by the BAC platform. Most notable is
a patient with imbalance of the 16p11.2 autism suscepti-
bility locus [12].
Diagnostic service
A total of 2,414 patients were tested as part of the diag-
nostic service. Overall, 24% of patients tested had copy
number variants (CNVs) not represented in the DGV,
and therefore considered to be potentially pathogenic
Figure 1 Array CGH diagnostic service workflow. This example illustrates the diagnostic workflow for two patients, one of whom has a
previously undetected imbalance of potential clinical significance. Yellow shading signifies automated procedures (we plan to also automate
labelling, hybridisation and washing).
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deletions (range 2 kb to 19.215 Mb), 300 duplications
(range 12 kb to 34.086 Mb) and 27 triplications (range
26 kb to 1.786 Mb). The smallest imbalance was a 2 kb
(3 probes) intragenic deletion within ZNF519, a zinc fin-
ger gene involved in regulation of transcription. Parental
samples for inheritance studies of this imbalance have
not yet been received.
All patients with imbalance not represented in the
DGV were followed up by other techniques or repeat
arrays prior to reporting. Parental samples were
requested in all cases, but only received for 40%. These
inheritance studies showed that de novo imbalances
accounted for 35% of findings for patients tested after a
normal karyotype, and 13% of findings from first line
tests (Figure 2). At least 89% of the abnormalities
detected by first line testing would not have been
detected by karyotype analysis (assuming a 3 Mb detec-
tion threshold for imbalance detection by G-banded
chromosome analysis). Overall, 14% of imbalances
detected fell within known sites of recurrent microdele-
tion/duplication.
Discussion
Array CGH testing does not detect balanced rearrange-
ments, and therefore may miss a clinically significant
karyotype where a de novo balanced rearrangement may
be disrupting gene function. We therefore carried out
an audit of postnatal karyotype results at our Centre
which showed that over this period 0.0001% of samples
had a de novo reciprocal translocation. Inherited trans-
locations would be considered incidental findings,
which, although potentially of value for reproductive
counselling for the parents, would not be relevant to the
proband’s referral. The increase in detection rate of
chromosome imbalance using our strategy is therefore a
major benefit, whereas the number of clinically signifi-
cant chromosome rearrangements that remain unde-
tected is extremely low.
The validation study indicated that the oligonucleotide
approach was robust and cost-effective, as well as having
a higher resolution than BAC arrays (see Tables 1 and 2),
with no false positive findings when followed up with
Table 1 Patients tested on BAC and oligo array platforms
with concordant results.
Patient BAC array result Oligo array result
1 2q33.1 × 3 (0.3-1.7 Mb) 2q33.1 × 3 (0.6 Mb)
2 7p12.1 × 3 (0.2-2.6 Mb) 7p12.1 × 3 (0.8 Mb)
3 14q12 × 3 (0.2-2.1 Mb) 14q12 × 3 (0.4 Mb)
4 19q12 × 1 (0.2-1.8 Mb) 19q12 × 1 (0.7 Mb)
5 Xp22.12p22.13 × 3 (0.8-2.0 Mb) Xp22.12p22.13 × 3 (0.8 Mb)
6 Xp11.22 × 2 (0.2-1.6 Mb) Xp11.22 × 2 (0.3 Mb)
Table 2 Patients tested on BAC and oligo array platforms
with discordant results.
Patient BAC array result Oligo array result
1 None 1q44 × 3 (0.3 Mb)
2 None 9q33 × 1 (0.2 Mb)
3 19q13 × 3 (0.2 Mb) 14q32 × 3 (0.2 Mb),
19q13 × 3 (0.1 Mb)
4 None 16p11 × 1 (3.0 Mb)
5 None 16p11 × 3 (0.2 Mb)
6 None 17p13 × 3 (0.5 Mb)
Table 3 Results from diagnostic service.
All oligo arrays
(service)
Oligo arrays following normal karyotype Oligo arrays as first line test
Total patients 2414 1245 1169
Abnormal patients 585 (24%) 325 (26%) 260 (22%)
- inherited 169 97 72
- de novo 63 52 11
- unknown inheritance 353 176 177
Table 4 Imbalances detected during diagnostic service (some patients carried more than one region of imbalance).
All oligo arrays
(service)
Oligo arrays following normal karyotype Oligo arrays as first line test
Total imbalances 715 404 311
- deletion 374 223 151
- duplication 300 155 145
- triplication 27 18 9
- marker 1 1
- whole chromosome 13 (incl. 7 mosaic) 8 (incl. 3 mosaic) 5 (incl. 4 mosaic)
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samples with abnormal karyotypes were tested. The
choice of the 4 × 44 K array platform was pragmatic,
with the aim of maximising detection of clinically signifi-
cant imbalances whilst minimising costs.
This approach was therefore introduced as a diagnos-
tic test in May 2008, in tandem with a comprehensive
education initiative for local users of the service. Since
then, 2,414 patients have been tested, with an overall
imbalance detection rate of 24% (excluding previously
published population polymorphisms (see above)). Pre-
viously published reports of detection rates in cohorts of
patients with congenital anomalies, mental disability or
dysmorphism, are heterogeneous in design and applica-
tion; those reporting cohorts of ≥ 100 patients include
those using tiling-path BAC arrays [13], 1 Mb BAC
arrays [14-16], targeted BAC arrays [17-19], and oligo-
nucleotide arrays [20-22]. The majority of patients in
these cohorts had normal karyotypes, and some had also
had subtelomeric imbalance excluded using either FISH
or MLPA. The overall imbalance detection rates ranged
from ~8% (using targeted BAC arrays) [17] to 20%
(using 1 Mb BAC arrays [14] or oligonucleotide arrays
[22]). These previous studies therefore indicate that the
protocols described here, including the patient/patient
hybridisation strategy, did not compromise the diagnos-
tic yield in this cohort.
Figure 2 shows that de novo abnormalities were less
prevalent when testing was carried out as a first line test.
This is likely to be due to stringent selection for post-
karyotype array CGH of patients likely to carry submicro-
scopic imbalance, carried out by expert dysmorphologists
and clinical geneticists. The cohort of patients tested by
array CGH as a first line test included those with referrals
more likely to be associated with polygenic and multifac-
torial conditions such as autism and Attention Deficit
Hyperactivity disorder, where genome imbalance is less
likely to be found, but needs to be excluded. De novo
abnormalities are generally considered likely to be patho-
genic and causative of the patient’s phenotype, whilst it
has been suggested that inherited imbalances should be
classified as “false positive” f i n d i n g s[ 2 3 ] .H o w e v e r ,i n
some families, the carrier parent may show mild manifes-
tation of the clinical phenotype affecting the child, and
expert phenotypic assessment of the carrier parent is
necessary to ascertain this; indeed, in our patient group
we have found families where the imbalance was present
in more than one other family member, all of whom had
phenotypes that were very much milder than that of the
proband. The possibility that a deletion unmasks a reces-
sive allele in the proband is another reason for careful
consideration of the gene content of inherited as well as
de novo imbalances. As more information on the function
and copy-number sensitivity of genes is accumulated, the
interpretation of such findings is likely to become more
straightforward.
Rationale for service strategy
The protocols described here were developed with the
aim of providing an array CGH service as a first line
test with little or no additional cost over and above that
of our current karyotype analysis. This cost includes
confirmatory testing of detected imbalance and subse-
quent inheritance studies.
The following factors contributed to reducing costs
and increasing efficiency of array CGH testing:
i) Patient/patient hybridisation: this strategy halved
consumable costs, and increased the efficiency of
analysis (for normal arrays, only one analysis was
required for two patients). The disadvantage of this
approach is that, were patients with the same
imbalance to be hybridised against each other, the
abnormality would not be detected (two patients
with deletion and duplication of the same region
respectively would be detected). Our protocol
therefore included a careful consideration of
patient referral information when constructing run
sheets for hybridisation (phenotype mismatching),
with the aim of reducing the incidence of missed
abnormalities. However, with the sparse clinical
information provided on many referral forms, some
imbalances may have been missed. Data from our
cohort suggests a less than 1 in 25,000 chance of
Figure 2 Comparison of de novo imbalance detection rates.
Proportion of de novo findings in first line array CGH and post-
normal karyotype array CGH cohorts. Higher rates of de novo
findings in the post-normal karyotype cohort reflect the stringent
clinical selection of these patients; these patients would have been
diagnosed at an earlier stage had array CGH been carried out as the
first line test.
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most common finding, present in 15 (~0.62% of
patients) even without phenotype mismatching.
Furthermore, the abnormality pick-up rate for array
CGH testing is considerably higher than for karyo-
type analysis, and any abnormalities missed as a
consequence of the hybridisation strategy would
likely be beyond the resolution of G-banded
chromosome analysis.
ii) Batch testing: processing of multiple samples for
labelling, clean-up and hybridisation considerably
reduced the technical time required for testing,
allowing a throughput of 96 samples/week.
iii) Robotics: automating DNA purification reduced
technical input time, and increased consistency of
processing. We aim also to automate DNA labelling
in the near future to reduce costs and reporting
times further, to allow increased throughput, and to
improve quality and consistency.
iv) Dedicated IT resources: a database application
was designed and built during the validation phase
of this study. This allowed rapid processing of infor-
mation, audit, sample tracking and construction of
run sheets, with click-through links to internet
resources, in particular the DGV, to expedite diagno-
sis and interpretation of findings.
The combination of the above resources and strategies
has enabled us to offer this test, including confirmatory
and inheritance follow-up testing, at the same cost as
karyotype analysis. We recognise that other centres will
have different financial and staffing constraints and may
not have access to some of the equipment and expertise
required, but nevertheless we feel that aspects of this
approach may be of interest to those wishing to intro-
duce array CGH testing into their diagnostic service.
The clinical utility and cost-effectiveness of array CGH
have been discussed in previous papers, which con-
cluded that, even without the increases in efficiency
described in this paper, array CGH results in a cost per
diagnosis less than that for karyotype analysis [24], and
predicts that array CGH is likely to become the genetic
test of choice for patients with suspected copy number
imbalance [25].
Conclusions
This study demonstrates the feasibility of using oligonu-
cleotide array CGH as a first line diagnostic test in place
of G-banded chromosome analysis for genome-wide
constitutional imbalance. This approach can be imple-
mented with minimal cost implications using the proto-
cols described. Array CGH provides a substantially
higher diagnostic yield than G-banded chromosome
analysis, thereby alleviating the burden of further clinical
investigations, and is providing valuable information on
the link between gene copy number and expression of
abnormal phenotype.
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